tradingkey.logo

Humacyte tumbles on planned equity raise

ReutersMar 25, 2025 8:21 PM

Shares of biotech firm Humacyte HUMA.O down 23.5% to $2.20 post-market after stock offering news

Durham, North Carolina-based firm announces proposed stock offering without disclosing deal size

Co intends to use net offering proceeds to fund commercialization of its implant Symvess for patients with extreme blood vessel injury

TD Cowen, Barclays and BTIG jt bookrunners

With ~122.65 mln shares outstanding, co has ~$353 mln market cap, per LSEG data

HUMA shares finished Tuesday's session down 13.4% at $2.88. YTD, stock down 43%

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI